Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. (NASDAQ: CRVO) generates frequent news flow as a clinical-stage biotechnology company developing neflamapimod for dementia with Lewy bodies (DLB) and other age-related brain disorders. The company’s updates often center on clinical data releases, regulatory interactions, and corporate developments tied to its lead program.
Investors following CRVO news can expect detailed announcements on results from the Phase 2b RewinD-LB trial in DLB, including subgroup analyses, biomarker findings, and longer-term extension data. CervoMed has reported that neflamapimod treatment in DLB was associated with effects on the Clinical Dementia Rating – Sum of Boxes (CDR-SB), the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC), and plasma biomarkers such as glial fibrillary acidic protein (GFAP), Aβ42/40 ratio, and neurofilament light. These news items provide insight into how the company interprets clinical and biomarker outcomes in its target population, particularly patients with a low likelihood of Alzheimer’s disease co-pathology.
CervoMed’s news flow also includes regulatory milestones, such as written feedback from the U.S. Food and Drug Administration aligning on key aspects of the planned Phase 3 trial design in DLB. Articles may describe planned trial parameters, enrichment strategies using plasma ptau181, and the role of CDR-SB as the primary endpoint. Additional coverage highlights participation in scientific conferences, presentations at dementia and neurology meetings, and dissemination of new analyses of trial data.
Beyond clinical and regulatory updates, CRVO news features quarterly financial results, grant funding details, and changes to the company’s leadership and board composition. Announcements of executive appointments, board expansions, and investor conference participation help contextualize CervoMed’s preparation for late-stage development and potential commercialization of neflamapimod. This news page aggregates these items so readers can track how scientific results, regulatory feedback, and corporate actions evolve over time.
CervoMed (NASDAQ: CRVO) presented Phase 2b RewinD-LB analyses at AD/PD 2026 showing greater clinical benefit from neflamapimod in DLB patients with lower plasma pTau181 (indicative of absent AD co-pathology).
Within-participant comparisons show CDR-SB differences up to -1.11 (p=0.005) in the lowest pTau181 subgroup, a planned Phase 3 enrichment cutoff of <21 pg/mL, and a pharmacologic activity threshold of Ctrough 4 ng/mL.
CervoMed (NASDAQ: CRVO) reported positive Phase 2b RewinD-LB results and regulatory alignment for a planned Phase 3 in dementia with Lewy bodies (DLB).
The company selected 50 mg TID neflamapimod for the Phase 3 (~300 patients) and expects multiple catalysts in H2 2026. Cash was $20.9M at year-end 2025 with an estimated ~six-month runway; full-year 2025 net loss was $27.0M.
CervoMed (NASDAQ: CRVO) will present Phase 2b RewinD-LB analyses at AD/PD 2026 in Copenhagen, March 17-21, 2026. Presentations include an oral talk on March 21 and a symposium on March 20.
New secondary analyses by pre-specified plasma pTau181 and PK/PD data further support the planned Phase 3 dosing regimen and the chosen patient-enrichment cutoff for DLB patients without Alzheimer’s co-pathology.
CervoMed (NASDAQ: CRVO) announced management will participate in investor conferences in March 2026, including 1x1 investor meetings at the Leerink Global Healthcare Conference on March 11, 2026, and a fireside chat plus meetings at the 38th Annual ROTH Conference on March 23, 2026.
The ROTH fireside chat is scheduled for 12:00–12:30 PM PT on March 23, 2026; the webcast will be accessible in the Investor section of CervoMed's website.
CervoMed (NASDAQ: CRVO) completed a Phase 1 healthy volunteer study evaluating a new, stable crystal form of neflamapimod and selected 50 mg three times daily (TID) as the dosing regimen for its planned Phase 3 trial in dementia with Lewy bodies (DLB).
The company says the stable crystal form's pharmacokinetic profile largely overlaps with the clinically active DP Batch B from the Phase 2b extension; dose is increased to ensure target plasma concentrations are achieved.
CervoMed (NASDAQ: CRVO) announced on Feb 18, 2026 that neflamapimod was selected for inclusion in the UK EXPERTS-ALS platform to evaluate potential ALS treatments.
The randomized, multicenter, open-label trial will measure neurofilament light chain (NfL) in blood; initial evaluation targets ~35 patients for 18–24 weeks, with potential expansion to 80. Trial costs are funded by the UK NIHR and major motor neuron disease charities; first dosing expected by end of 2026.
CervoMed (NASDAQ: CRVO) reported late-breaking Phase 2b RewinD-LB results showing neflamapimod significantly slowed clinical progression in dementia with Lewy bodies (DLB) and reduced the biomarker plasma GFAP. In an extension phase using a new capsule batch (DP Batch B), CDR-SB worsening was 52% lower versus DP Batch A at week 16 (and 82% lower in patients with ptau181 <21 pg/mL). Effects were durable to 32 weeks and correlated with GFAP reductions (median -16.0; p<0.0001). Initial randomized phase did not meet the primary endpoint due to lower-than-expected bioavailability with DP Batch A. CervoMed plans a Phase 3 registrational trial in H2 2026.
CervoMed (NASDAQ: CRVO) presented Phase 2b RewinD-LB biomarker data on December 1, 2025 at CTAD showing neflamapimod reduced plasma GFAP, increased the Aβ42/40 ratio, and trended to lower NfL in dementia with Lewy bodies (DLB).
Key controlled comparison used participants who received a higher-bioavailability capsule batch (DP Batch B) during a 32-week open-label extension versus their prior placebo period; GFAP change correlated with clinical CDR-SB change (r=0.35, p=0.036).
CervoMed (NASDAQ: CRVO) announced that neflamapimod will be featured in two presentations at the 18th CTAD conference, Dec 1–4, 2025 in San Diego.
A late-breaking oral presentation on Dec 4, 2:10 p.m. PT will present full results from the Phase 2b RewinD-LB trial at 32 weeks, delivered by Prof. John-Paul Taylor. A poster (Poster 071) on Dec 1–2 reports that neflamapimod significantly lowers plasma GFAP and examines effects on NfL and Aβ42/40. Plasma assays were run at the Neurochemistry Laboratory, Amsterdam UMC under Prof. Charlotte Teunissen.
CervoMed (NASDAQ: CRVO) reported Q3 2025 results and clinical progress on neflamapimod for dementia with Lewy bodies (DLB). The company said it aligned with the FDA on Phase 3 trial design and plans to meet other global regulators before initiating a global pivotal trial in H2 2026. Phase 2b RewinD-LB 32-week data showed a 64% risk reduction in clinically significant worsening (CDR-SB ≥1.5) in patients with low AD co-pathology (p<0.001) and correlated reductions in plasma GFAP biomarker. Cash on hand was $27.3M (Sept 30, 2025), with funding expected into the third quarter of 2026. Q3 net loss was $7.7M.